Shattuck Labs, Inc. (STTK)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Taylor H. Schreiber M.D., Ph.D.
|
Co-Founder, CEO & Director | 876.23k | -- | 1980 |
|
Mr. Andrew R. Neill M.B.A.
|
Chief Financial Officer | 678.21k | -- | 1986 |
|
Dr. Arunthathy Nirmalini Pandite M.B.A., M.D.
|
Chief Medical Officer | 734.9k | -- | 1959 |
|
Mr. Brad Huckabee
|
Vice President of Accounting & SEC reporting | -- | -- | -- |
|
Dr. Abhinav A. Shukla Ph.D.
|
Chief Technical Officer | 567.4k | -- | 1973 |
|
Mr. Suresh de Silva Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Dr. Stephen Stout J.D., Ph.D.
|
General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | -- | -- | 1975 |
|
Ms. Casi DeYoung
|
Chief Business Officer | 523.48k | -- | 1971 |
|
Dr. Thomas Lampkin Pharm.D.
|
Senior Vice President of Regulatory Affairs | -- | -- | -- |
|
Ms. Kelli Collin M.B.A., M.S.
|
Senior Vice President of Quality | -- | -- | -- |
Shattuck Labs, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 40
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Corporate Governance
Upcoming Events
November 12, 2026 at 1:30 PM UTC
Shattuck Labs, Inc. Earnings Date
